Literature DB >> 3134490

The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.

C A Wood1, D R Norton, S J Kohlhepp, P W Kohnen, G A Porter, D C Houghton, R E Brummett, W M Bennett, D N Gilbert.   

Abstract

The influence of dosage regimen on the nephrotoxicity, ototoxicity, and antibacterial efficacy of tobramycin was assessed in Fisher rats with Pseudomonas aeruginosa subcutaneous abscesses. A subcutaneous tobramycin dose of 10 mg/kg every 4 h resulted in peak and trough serum concentrations that approximated those currently recommended for patients. Subsequently, the influence of this subcutaneous dosage regimen was compared with three other regimens that administered the same total daily dose: 20 mg every 8 h, 30 mg every 12 h, and 60 mg every 24 h. Renal injury was assessed by measuring inulin clearance and in vivo synthesis of renal DNA and by histopathology. Cochlear histology was also assessed. The number of P. aeruginosa per abscess was quantitated. In animals with infected abscesses, there was a consistent trend of greater kidney injury with the more-frequent dosage regimens. There was no evidence of cochlear toxicity in any group. All regimens were equally effective in reducing the number of P. aeruginosa in subcutaneous abscesses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134490     DOI: 10.1093/infdis/158.1.13

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

Review 1.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

3.  Influence of the rate of intravenous administration of eliprodil (SL 82.0715), a new anti-ischaemic agent, on its distribution in rat plasma and tissues.

Authors:  D Garrigou-Gadenne; J P Thenot; P L Morselli
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

4.  A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.

Authors:  D Czock; M Giehl; F Keller
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

5.  Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.

Authors:  C A Wood; H C Finkbeiner; S J Kohlhepp; P W Kohnen; D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

7.  Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Mark R Deziel; Kris Zager; Qingmei Weng; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis.

Authors:  B Fantin; B Pangon; G Potel; J M Vallois; F Caron; A Bure; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

9.  Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics.

Authors:  F Fauvelle; P Perrin; L Belfayol; M Boukari; P Cherrier; A M Bosio; M Tod; J M Coulaud; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.

Authors:  M Blatter; U Fluckiger; J Entenza; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.